alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 68 studies with an author at Chinese Academy of Sciences (CN) (page 2 of 3) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of these 68 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Constipation preceding stroke, dementia and Parkinson’s disease in middle-aged and older adults: a population-based cohort study

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Age and Ageing 2025-08-29

Out of 462,327 eligible participants, those with constipation were associated with higher incidence of three outcome diseases (1415/20,263 [7.0%]) than those without (18,848/442,064 [4.3%]), with adjusted hazard ratio (HR) being 1.35 [1.27-1.42]. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A Dementia Classification Framework Using Frequency and Time-Frequency Features Based on EEG Signals

✓ Peer-reviewed alzhub usefulness score 51 out of 100. IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society 2019-04-04

Alzheimer's disease (AD) accounts for 60%-70% of all dementia cases, and clinical diagnosis at its early stage is extremely difficult. 2 key findings →

Participants: 40 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Molecular neurodegeneration 2022-06-03

Triggering receptor expressed on myeloid cells 2 (TREM2) is a single-pass transmembrane immune receptor that is mainly expressed on microglia in the brain and macrophages in the periphery. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Autophagy 2019-04-06

We found that pharmacological activation of PPARA by the PPARA agonists gemfibrozil and Wy14643 induces autophagy in human microglia (HM) cells and U251 human glioma cells stably expressing the human APP (amyloid beta precursor protein) mutant (APP-p.M671L) and this effect is PPARA-dependent. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effect of acupuncture in mild cognitive impairment and Alzheimer disease: a functional MRI study

✓ Peer-reviewed alzhub usefulness score 50 out of 100. PloS one 2012-08-20

We aim to clarify the mechanisms of acupuncture in treating mild cognitive impairment (MCI) and Alzheimer disease (AD) by using functional magnetic resonance imaging (fMRI). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

TREM2, microglia, and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Mechanisms of ageing and development 2021-01-28

Triggering receptor expressed on myeloid cells 2 (TREM2) has been suggested to play a crucial role in Alzheimer's disease (AD) pathogenesis, as revealed by genome-wide association studies (GWAS). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

PARylation regulates stress granule dynamics, phase separation, and neurotoxicity of disease-related RNA-binding proteins

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Cell research 2019-02-06

Mutations in RNA-binding proteins (RBPs) localized in ribonucleoprotein (RNP) granules, such as hnRNP A1 and TDP-43, promote aberrant protein aggregation, which is a pathological hallmark of various neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A Drosophila model for TDP-43 proteinopathy

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2010-01-26

Neuropathology involving TAR DNA binding protein-43 (TDP-43) has been identified in a wide spectrum of neurodegenerative diseases collectively named as TDP-43 proteinopathy, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Progressive structural alterations in the cerebral small vessel disease with cognitive impairment and vascular dementia

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of Alzheimer s Disease 2025-09-03

BackgroundThe progression of cerebral small vessel disease (CSVD) leads to cognitive decline, which can be categorized into subcortical vascular mild cognitive impairment (svMCI) and vascular dementia (VaD).ObjectiveThis research aimed to examine the structural changes in gray (GM) and white matter (WM) in the brain across the disease spectrum. 5 key findings →

Design: longitudinal study Participants: 26 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase

✓ Peer-reviewed alzhub usefulness score 48 out of 100. The Journal of biological chemistry 2008-04-23

Accumulation of senile plaques composed of amyloid beta-peptide (Abeta) is a pathological hallmark of Alzheimer disease (AD), and Abeta is generated through the sequential cleavage of amyloid precursor protein (APP) by beta- and gamma-secretase. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impaired functional connectivity of the thalamus in Alzheimer's disease and mild cognitive impairment: a resting-state fMRI study

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Current Alzheimer research 2013-09-01

Our results revealed disease severity-related alterations of the thalamo-default mode network and thalamocortical connectivity in AD and MCI patients. 4 key findings →

Participants: 35 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Nickel-based nanomaterials: a comprehensive analysis of risk assessment, toxicity mechanisms, and future strategies for health risk prevention

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Nanobiotechnology 2025-03-14

Nickel-based nanomaterials (NBNs) have seen a surge in usage across a variety of applications. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Hippocampal shape analysis of Alzheimer disease based on machine learning methods

✓ Peer-reviewed alzhub usefulness score 46 out of 100. AJNR. American journal of neuroradiology 2007-08-01

Subtle and spatially complex deformation patterns of hippocampus between patients with AD and healthy control subjects can be detected by machine learning methods. 2 key findings →

Participants: 19 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Abnormal salience network in normal aging and in amnestic mild cognitive impairment and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Human brain mapping 2013-11-12

The salience network (SN) serves to identify salient stimuli and to switch between the central executive network (CEN) and the default-mode network (DMN), both of which are impaired in Alzheimer's disease (AD)/amnestic mild cognitive impairment (aMCI). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Glymphatic activity in behavioral variant frontotemporal dementia: Link with vascular function and astrocytic activation

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s & Dementia 2025-08-01

Glymphatic activity in bvFTD correlated strongly with vascular dysfunction and astrocytic activation, and was associated with brain changes and clinical severity. 5 key findings →

Participants: 61 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Acta pharmacologica Sinica 2006-01-01

Huperzine A (HupA), a novel alkaloid isolated from the Chinese herb Huperzia serrata, is a potent, highly specific and reversible inhibitor of acetylcholinesterase(AChE). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cognitive training reorganizes lateralization of fronto-parietal network in vascular cognitive impairment

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain Communications 2025-01-01

These findings suggest that subcortical VCIND modifies the relationship between FPN lateralization and cognitive functions, rather than altering the lateralization pattern itself. 1 key finding →

Participants: 30 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed